The stock of Sage Therapeutics Inc (NASDAQ: SAGE) has decreased by -0.40 when compared to last closing price of 12.39.Despite this, the company has seen a loss of -5.84% in its stock price over the last five trading days. Business Wire reported 2024-05-07 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor conferences in May: 2024 RBCCM Global Healthcare Conference (New York, NY): fireside chat on Tuesday, May 14, 2024 at 11:30 a.m. ET. BofA Securities 2024 Health Care Conference (Las Vegas, NV): fireside chat on Wednesday, May 15, 2024 at 10:00 a.m. PT.
Is It Worth Investing in Sage Therapeutics Inc (NASDAQ: SAGE) Right Now?
The 36-month beta value for SAGE is at 0.95. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 6 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SAGE is 49.11M, and currently, shorts hold a 18.96% of that float. The average trading volume for SAGE on May 10, 2024 was 1.07M shares.
SAGE’s Market Performance
SAGE’s stock has seen a -5.84% decrease for the week, with a -24.98% drop in the past month and a -48.11% fall in the past quarter. The volatility ratio for the week is 4.99%, and the volatility levels for the past 30 days are at 6.76% for Sage Therapeutics Inc The simple moving average for the past 20 days is -10.60% for SAGE’s stock, with a -41.08% simple moving average for the past 200 days.
Analysts’ Opinion of SAGE
Many brokerage firms have already submitted their reports for SAGE stocks, with BofA Securities repeating the rating for SAGE by listing it as a “Underperform.” The predicted price for SAGE in the upcoming period, according to BofA Securities is $14 based on the research report published on April 17, 2024 of the current year 2024.
Deutsche Bank, on the other hand, stated in their research note that they expect to see SAGE reach a price target of $21. The rating they have provided for SAGE stocks is “Hold” according to the report published on December 12th, 2023.
SAGE Trading at -28.17% from the 50-Day Moving Average
After a stumble in the market that brought SAGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.43% of loss for the given period.
Volatility was left at 6.76%, however, over the last 30 days, the volatility rate increased by 4.99%, as shares sank -25.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.28% lower at present.
During the last 5 trading sessions, SAGE fell by -5.84%, which changed the moving average for the period of 200-days by -70.51% in comparison to the 20-day moving average, which settled at $13.59. In addition, Sage Therapeutics Inc saw -43.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SAGE starting from Barrett Elizabeth, who purchase 2,000 shares at the price of $18.64 back on Aug 09 ’23. After this action, Barrett Elizabeth now owns 3,000 shares of Sage Therapeutics Inc, valued at $37,279 using the latest closing price.
Stock Fundamentals for SAGE
Current profitability levels for the company are sitting at:
- -5.95 for the present operating margin
- 0.96 for the gross margin
The net margin for Sage Therapeutics Inc stands at -5.53. The total capital return value is set at -0.77. Equity return is now at value -54.72, with -50.61 for asset returns.
Based on Sage Therapeutics Inc (SAGE), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -128.47. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -62.65.
Currently, EBITDA for the company is -511.68 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 6.28. The receivables turnover for the company is 6.45for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.22.
Conclusion
In conclusion, Sage Therapeutics Inc (SAGE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
